Lipocine Announces Positive Top-Line Phase IIb Study Results
Lipocine Inc. recently reported positive top-line results from a Phase IIb clinical study of LPCN 1111, a novel oral testosterone replacement therapy (TRT) product candidate. The primary objectives of the study were to determine the Phase III dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males.
The Phase IIb clinical trial was a randomized, open label, two-period, multi-dose PK study that enrolled hypogonadal males into five treatment groups. Each of the 12 subjects in a group received treatment for 14 days. Results of the Phase IIb study suggest that the primary objectives were met, including identifying the dose expected to be tested in a Phase III study. Good dose-response relationship was observed over the tested dose range in the Phase IIb study. The target Phase III dose met primary and secondary end points. LPCN 1111 was well tolerated with no drug-related severe or serious adverse events reported.
“We are pleased to report these positive top-line results, as these results reinforce our belief that LPCN 1111 represents a promising product candidate for once daily administration of testosterone,” said Dr. Mahesh Patel, President and CEO of Lipocine Inc. “Based on this progress, we plan to meet with the US FDA to discuss Phase III development plans.”
LPCN 1111, a novel prodrug of testosterone, originated with and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. LPCN 1111 comprises a novel prodrug different from the testosterone ester in LPCN 1021, and it uses Lipocine’s proprietary solubilization technology to improve systemic absorption to give effective testosterone levels.
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes three development programs LPCN 1021, LPCN 1111, and LPCN 1107. LPCN 1021, a twice-daily oral testosterone replacement therapy product candidate, was well tolerated and met primary efficacy end point in Phase III testing, which utilized 24-hour pharmacokinetic data for dose adjustments. LPCN 1111, a novel prodrug of testosterone, originated with and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase II testing. LPCN 1107, the potentially first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, has been granted orphan drug designation by the FDA. An End of Phase II meeting with the FDA was recently completed. For more information, visit www.lipocine.com.
Total Page Views: 1173
